Dr. Ming Yang is the Founder, President & CEO of Bright Biologics LLC. He has over 20 years of biopharma industry experience in both large and small molecule drug research & development. He received M.D. in China and Doctoral Degree in Molecular Pharmacology in Germany. He finished Post-doctoral training first in Molecular Immunology at University of Illinois at Chicago and then in Molecular Oncology at Amgen.

Dr. Yang has held several scientific leadership positions through his career. Prior to founding Bright Biologics, Dr. Yang was Group Leader of Cell Biology at Hengenix Biotech, where he initiated and established a large screening platform of in vitro cell-based functional assays for oncology drug targets, leading to advance of multiple projects to IND and phase I. He also led several high-profile projects directly at Hengenix, including VHH and bispecific antibody projects. Two of the projects were advanced into phase I. Prior to joining Hengenix, Dr. Yang was a Sr. Scientist at Gilead, where he led an in vitro cell-based assay group for research & drug discovery on metabolic drug targets. His broad knowledge and experience in clinical medicine, cell and molecular biology, and antibody engineering provide a unique strategic vision for the company’s R&D.

Dr. Yang is a leading inventor of multiple patents of bispecific antibodies. He authored or co-authored more than 30 scientific publications in peer-reviewed journals and is a first or corresponding author for 13 publications.